[EN] 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS 7-HYDROXY-PYRAZOLO-[1,5-A] PYRIMIDINE ET LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR CCR2
申请人:PROXIMAGEN LTD
公开号:WO2012041817A1
公开(公告)日:2012-04-05
The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.
式(I)的化合物是CCR2受体的拮抗剂,其中R1-7和A如权利要求中所定义。
7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS
申请人:Boyd Joe William
公开号:US20130252951A1
公开(公告)日:2013-09-26
The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R
1-7
and A are as defined in the claims.
式(I)的化合物是CCR2受体的拮抗剂,其中R1-7和A如权利要求中所定义。
Highly diastereoselective 1,3-dipolar cycloadditions of chiral non-racemic nitrones to 1,2-diaza-1,3-dienes: an experimental and computational investigation
作者:Roberta Majer、Olga Konechnaya、Ignacio Delso、Tomas Tejero、Orazio A. Attanasi、Stefania Santeusanio、Pedro Merino
DOI:10.1039/c4ob01371a
日期:——
Asymmetric 1,3-dipolarcycloadditions between 1,2-diaza-1,3-dienes and chiral non-racemic nitrones to give 3-substituted-5-diazenyl isoxazolidines were studied both experimentally and theoretically. Whereas cyclic nitrones provide complete selectivity for the cycloaddition reaction (only one isomer is obtained), acyclic nitrones derived from D-glyceraldehyde and D-galactose lead to 1 : 1 mixtures of
Expeditious Synthesis of 1,2-Diaminoimidazoles under Solvent-Free Conditions
作者:Paolino Filippone、Orazio A. Attanasi、Lucia De Crescentini、Gianfranco Favi、Fabio Mantellini、Stefania Santeusanio
DOI:10.1055/s-2004-815432
日期:——
1,2-Diaminoimidazoles are obtained in good yields by reaction of 1,2-diaza-1,3-butadienes with cyanamide at 50 °C under solvent-free conditions. These compounds are important intermediates for the synthesis of imidazo[1,2-b][1,2,4]triazines.
1.4-Dihydropyrazine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln
申请人:BAYER AG
公开号:EP0149237A2
公开(公告)日:1985-07-24
Die vorliegende Erfindung betrifft neue 1.4-Dihydropyrazine der allgemeinen Formel I
in welcher R, R1, R2, R3 und R4 die in der Beschreibung angegebene Bedeutung haben, mehrere Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln, insbesondere in kreislaufbeeinflussenden Mitteln.